Anavex Life Sciences Corp. 8-K Filing
Ticker: AVXL · Form: 8-K · Filed: Nov 14, 2025 · CIK: 1314052
| Field | Detail |
|---|---|
| Company | Anavex Life Sciences Corp. (AVXL) |
| Form Type | 8-K |
| Filed Date | Nov 14, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Anavex Life Sciences Corp. (ticker: AVXL) to the SEC on Nov 14, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch Registered Common Stock, par value $0.001 per share AVXL The Nasdaq Stock Mar).
How long is this filing?
Anavex Life Sciences Corp.'s 8-K filing is 2 pages with approximately 493 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2025-11-14 07:42:01
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 per share AVXL The Nasdaq Stock Mar
Filing Documents
- e7038_8-k.htm (8-K) — 24KB
- e7038_ex99-1.htm (EX-99.1) — 13KB
- 0001731122-25-001536.txt ( ) — 202KB
- avxl-20251114.xsd (EX-101.SCH) — 3KB
- avxl-20251114_lab.xml (EX-101.LAB) — 33KB
- avxl-20251114_pre.xml (EX-101.PRE) — 22KB
- e7038_8-k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 14, 2025, Anavex Life Sciences Corp. (the "Company") issued a press release announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a negative trend vote following an oral explanation of the Company's Marketing Authorization Application (MAA) for blarcamesine. The Company intends to request a re-examination of the CHMP opinion upon its formal adoption, including providing relevant biomarker data, based on feedback and continued guidance from the CHMP, EMA and the Alzheimer's disease community. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference, including the cautionary statement on forward-looking statements included in the press release. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NO. DESCRIPTION LOCATION 99.1 Press release dated November 14, 2025 Filed herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANAVEX LIFE SCIENCES CORP. By: /s/ Christopher Missling Name: Christopher Missling, PhD Title: Chief Executive Officer Date: November 14, 2025